[Intravitreal bevacizumab for recurring choroidal neovascularisation]

Area of Science:

• Ophthalmology
• Vascular Biology
• Medical Treatments

Background:

• Choroidal neovascularization (CNV) can lead to vision loss, particularly in patients with limited ocular reserve.
• Previous treatments for CNV include laser coagulation and photodynamic therapy, but recurrences can occur.
• Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, has shown promise in treating neovascular eye diseases.

Observation:

• A 32-year-old female patient with a single functional eye experienced recurrent CNV despite prior treatments.
• Intravitreal bevacizumab was administered to the affected eye.
• Fluorescein angiography revealed significant leakage before treatment and minimal leakage after treatment.

Findings:

• Vision in the treated eye remained stable at 1.0 before and after intravitreal bevacizumab administration.
• Intravitreal bevacizumab successfully reduced vascular leakage associated with recurrent CNV.
• The treatment was considered despite risks due to positive prior experiences with bevacizumab in exudative age-related macular degeneration (AMD) and macular edema.

Implications:

• Intravitreal bevacizumab is a potential therapeutic option for recurrent and idiopathic CNV, especially in patients with limited treatment choices.
• This case highlights the efficacy of VEGF inhibition in managing complex CNV cases.
• Further clinical studies are warranted to confirm the long-term safety and efficacy of intravitreal bevacizumab for idiopathic CNV.